The coronavirus by pharma giant Pfizer and German company BioNTech recently announced that their coronavirus vaccine had reached over 90% effectiveness in those who showed no prior signs of infection.
Their results were based on an interim efficacy analysis done by an independent Data Monitoring Committee from the phase 3 clinical study, a body which supervises these trials to protect participants’ safety.
Among more than 40,000 participants, 94 confirmed infections were assessed. According to the two companies, the case split between those vaccinated and those who received a placebo showed the vaccine’s efficacy rate to be at over 90% seven days after the second dose, meaning that protection from the virus is acquired 28 days after the first dose.
Previously, White House coronavirus advisor Dr. Anthony Fauci said that a vaccine with 50 to 60% effectiveness would be passable.
A Pfizer board official said that it could be available in limited use as early as late December and widely available by quarter 3 of next year.
Pfizer chair and CEO Albert Bourla called the development “likely the most significant medical advance in the last 100 years”, accounting for its impact on public health and the global economy.
Despite the good news, delivery of the vaccines to other countries proves to be an obstacle, partly due to the fact that they need to be stored in containers cooled down to -94OF (-70OC).
Since the outbreak, researchers and scientists all over the world have worked at breakneck speed in the hopes of producing an effective vaccine to curb the spread of a virus that has claimed more than 1.2 million lives in less than a year.